ÂÜÀòÂÒÂ×

Raised in the family of mathematicians and engineers, Bojena was destined to join the analytical field. A desire to apply her technical abilities to making a difference in patient lives brought her to the unique department of Medical Cybernetics while in Medical School in Russia. In this department, medical science and analytics went hand to hand. This Medical Cybernetics experience guided Bojena to receive her BS degree in Microbiology from UCSB and MS degree in Biostatistics from UCLA. Bojena now has over 20 years of experience working in the pharmaceutical and biotech industry and is passionate about developing novel therapies for patients.

Bojena joined Revolution Medicines in 2019 and heads Quantitative Sciences comprised of Biostatistics and Translational Medicine groups where she applies her broad knowledge in clinical, biological, and statistical fields.

Previously Bojena has made substantial contributions to the clinical development and approval of BTK inhibitor CALQUENCE (Acalabrutinib) at Acerta Pharma (a subsidiary of AstraZeneca), has served in the role of global statistical lead for ENBREL (etanercept) at Amgen, and supported clinical and statistical teams working on developing vaccines and biologics at Vaxgen and Baxter.